Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,580.06
(
0.22%
)
US TECH 100
29,506.00
(
0.28%
)
Dow Jones
51,032.46
(
0.72%
)
Brent Oil
91.36
(
0.00%
)
Bitcoin
73,885.77
(
0.18%
)
News Focus
News Focus
Post# of 257661
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

bladerunner1717

Send PM Follow Ignore
Followers 36
Posts 5652
Boards Moderated 0
Alias Born 11/09/2003

bladerunner1717

Re: bladerunner1717 post# 6352

Sunday, 01/02/2005 5:30:26 PM

Sunday, January 02, 2005 5:30:26 PM

Post# of 257661
oops. I just noticed this tidbit:

"The ATIII LLC decided to discontinue development of this indication based on the level of additional data that would have been required to address the clinical development issues raised during the meeting with the FDA..."

What exactly were "the clinical development issues raised during the meeting with the FDA?"


Bladerunner
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up